

SPOTLIGHT ON EMERGING THERAPIES FOR PATIENTS WITH EGFR-POSITIVE NSCLC

Friday 26 March
2021

Symposium
12:50-14:20 CET

Channel 1

STEERING COMMITTEE
Rosario Garcia Campelo, **SPAIN**
Michael Thomas, **GERMANY**

FACULTY
Anne-Marie Dingemans,
THE NETHERLANDS
Nicolas Girard, **FRANCE**

This exciting symposium will be pre-recorded; however, you have the opportunity to submit your questions to the faculty during our live Q&A on Friday 26 March 2021, 13:50-14:20 CET.

LEARNING OBJECTIVES

After attending this symposium, participants should be able to:

- Describe the novel paradigms for TKI-resistant disease in advanced NSCLC patients with common EGFR mutations
- Evaluate the unmet needs for advanced NSCLC patients with EGFR exon 20 insertions
- Identify and review the latest advances of the emerging options in these patient populations

PROGRAM

SESSION	FACULTY
Welcome and introductions	Dr Rosario Garcia Campelo Prof. Michael Thomas
Reflect, adapt and aspire: A review of the NSCLC landscape, EGFR+ disease in focus	Prof. Anne-Marie Dingemans
Are we doing our best for patients with EGFR exon 20 insertions in advanced NSCLC?	Prof. Nicolas Girard
Key learnings and closing remarks	Dr Rosario Garcia Campelo Prof. Michael Thomas
Live Q&A/Panel-led discussion	All faculty